January 2026 Research Update

This month added two different kinds of real-world information about CAH treatment: what day-to-day care looks like for many newborns, and what happens in a small group of patients who switch to pump-delivered hydrocortisone. Together, these studies highlight that early-life monitoring and medication adjustment can be complex, and that alternative delivery methods are being explored for patients who remain hard to control on standard tablets. Both reports describe what was observed rather than proving that one approach is best for everyone. [1] [2]

In a multinational registry of 154 infants with 21-hydroxylase deficiency, electrolyte problems were common early on and improved by 90 days, but did not disappear for everyone. Hyponatremia and hyperkalemia were reported frequently overall, and blood pressure was recorded in less than one-third of infants, yet among those measured about 1 in 3 had hypertension. This paints a clearer picture that the first months often involve balancing salt-related labs and blood pressure checks, and that what gets measured and how often can vary across centers. [1]

In a small single-center group of 13 children and adolescents with primary adrenal insufficiency (mostly CAH) who were poorly controlled on oral hydrocortisone, continuous subcutaneous hydrocortisone infusion (CSHI) was followed by lower ACTH and lower adrenal androgen markers such as 17-OHP and androstenedione. Growth and body mass index stayed stable over a median follow-up of 48 months, and major safety issues were not reported, although one person stopped because of skin intolerance. Some CAH-related issues improved in some patients, including smaller testicular adrenal rest tumors and resumption of regular menstrual cycles in at least one adolescent. [2]

For families, the infant registry study mainly adds context for what can happen early in life: hospital stays, electrolyte disturbances, adrenal crises during hospitalizations, and uneven tracking of blood pressure across sites. It does not test a new medicine, but it helps explain why frequent lab checks and careful follow-up are often part of the first months. [1]

For patients who struggle with hormone control on oral hydrocortisone, the CSHI report gives an early signal that pump-based hydrocortisone can line up hormone levels more closely with treatment goals while keeping growth stable in a small group. Because this was a retrospective study in 13 patients without a comparison group, it cannot tell who will benefit most or how it compares with other approaches in broader care. For now, it mainly adds to the evidence base that delivery method may matter for some people, and that longer-term monitoring of outcomes beyond lab values is still needed. [2]

This month sharpened the message that getting the diagnosis right often depends on combining hormone patterns with genetic testing, especially when the presentation is unusual. Larger genetic studies showed that most people clinically diagnosed with 21-hydroxylase deficiency can have a causative CYP21A2 variant identified, and newer sequencing methods may simplify difficult cases. At the same time, several case reports showed how CAH can be mistaken for other conditions, or how other conditions can mimic key CAH lab findings. [3] [4] [5]

In 315 Asian Indian patients with CAH, CYP21A2 variants were detected in 94.3% of cases, and a small number of variant types made up most findings. This kind of large dataset helps clarify which genetic changes are more common in a specific population, and it also documents rarer and novel variants and gene conversion events. The main value for patients is better understanding of what genetic results may look like in real clinics, rather than a change in treatment. [3]

A separate diagnostic study in 34 clinically diagnosed patients reported that adaptive sampling long-read sequencing with a custom analysis tool confirmed CYP21A2-related CAH in 32 of 34 patients, and it could determine which variants were on which copy of the gene without parental testing in most cases. The report also described improved clarification of complex rearrangements like chimeras and deletions compared with standard methods. This adds an early, practical signal that newer DNA testing approaches may make difficult-to-analyze CYP21A2 results easier to resolve, although it was tested in a relatively small group. [4]

Several case reports showed where diagnostic confusion can happen when lab results or anatomy do not match typical CAH patterns. One adolescent treated as CAH was later found to have NR0B1-related adrenal hypoplasia congenita, where ACTH stayed high but adrenal androgens stayed low, and genetic testing identified an NR0B1 variant. Another case used urethroscopy in a 46,XX child reared as male to show internal structures consistent with fetal testicular function and to exclude CAH, leading to a diagnosis of 46,XX testicular DSD. [5] [6]

For many families, the genetic studies mainly matter by improving the chance of a clear name for the condition and a clear explanation of why it happened. The large Indian dataset supports that most people can receive a genetic finding, and the long-read sequencing work suggests that complex CYP21A2 results may be solved faster and with clearer variant phasing in some settings. These are advances in testing rather than proof of better health outcomes. [3] [4]

The case reports matter as reminders that a CAH label should fit the full pattern, not just one lab test or one physical sign. In the NR0B1 case, persistently low adrenal androgens despite high ACTH pointed away from CAH and genetic testing clarified the diagnosis; in the 46,XX testicular DSD case, endoscopy clarified anatomy and ruled out CAH when genetics were not available. What remains uncertain is how often these look-alike situations occur in routine care, because single cases cannot provide rates, but they do show the kinds of clues that can prompt a broader diagnostic workup. [5] [6]

This month included several individual stories and exploratory studies that expand the picture of CAH beyond day-to-day hormone control. The case reports showed that elevated steroid markers like 17-OHP can sometimes come from uncommon causes, and that severe virilization or genital differences can arise from several different conditions. In parallel, early research explored how other hormones (like thyroid hormone) may shift adrenal steroid production, and how early androgen exposure in CAH may relate to some adult social personality traits. [7] [8] [9] [10]

One case report described a woman with recurrent miscarriages whose elevated 17-OHP was traced to a single adrenal adenoma that secreted 17-OHP, confirmed by adrenal venous sampling and followed by surgical removal with normalization of 17-OHP and subsequent conception. This report matters because it shows that an abnormal 17-OHP result does not always mean inherited CAH, especially when the pattern is isolated and imaging finds an adrenal mass. It also suggests that tumor biology can involve mixed expression of steroid-producing enzymes, although this was exploratory tissue analysis. [7]

Several pediatric reports focused on severe or unusual presentations involving the adrenal glands and sex development. A fetus with ambiguous genitalia and a large ovarian cyst was diagnosed after birth with salt-wasting CAH, and the cyst was benign on pathology after surgery. Another report described a child with virilization and adrenal crisis who was initially misdiagnosed as late-onset CAH, but imaging and pathology revealed adrenocortical carcinoma with TP53 mutation consistent with Li-Fraumeni syndrome and rare extension into the heart. [11] [8]

A small case series of 7 Saudi patients described congenital lipoid CAH due to StAR deficiency, with all patients having homozygous STAR variants and remaining clinically stable on long-term steroid replacement. Most 46,XY individuals were raised female and underwent gonadectomy, and neonatal cholestasis was reported in two cases. This adds population-specific genetic information and reminds readers that not all CAH is due to CYP21A2. [12]

On the biology side, laboratory work using an adrenal cell model reported that thyroid hormone T3 shifted steroid production by lowering DHEA and DHEAS and modestly raising testosterone and androstenedione, along with changes in steroid-making genes. When the researchers looked at pediatric CAH patients, thyroid hormone blood tests showed only weak relationships with adrenal androgens and did not differ between well-controlled and hyperandrogenic visits. This combination suggests thyroid hormone can change adrenal steroid production in cells, but it did not show a strong two-way feedback signal in patients. [9]

A separate adult study used classical CAH as a model of early androgen exposure and found that women with CAH scored as more male-typical on measures like aggression, dominance, and tender-mindedness compared with women without CAH, while men with CAH did not differ from matched control men. This adds evidence that early hormone exposure may relate to certain average differences in adult social traits in women, without implying anything about any one person. The study focused on group-level questionnaire results and did not link traits to specific medical outcomes. [10]

Finally, a training-course study in people with differences of sex development (DSD) and families, which can include some people affected by CAH, reported improved diagnosis-specific knowledge at 6 months after a two-day program. Knowledge gains were seen in children, young adults, and parents, with the largest increase reported in children and adolescents. This adds evidence that structured education programs can improve understanding, though it did not test mental health or medical outcomes. [13]

One adult case report described extremely delayed recognition of classic CAH due to 21-hydroxylase deficiency in a 46,XX individual presenting as male, with large bilateral adrenal myelolipomas seen on imaging and CYP21A2 variants confirming the diagnosis. The report also described missed Mullerian remnants on initial imaging and highlighted communication challenges around discussing karyotype. It illustrates how long-term androgen excess can shape anatomy and life experience when CAH is not identified early. [14]

For patients, these reports mostly add understanding rather than changing routine care. The adrenal adenoma case and the adrenal cancer case both show that CAH-like lab results or virilization can sometimes come from other adrenal conditions, which is important context when a presentation is unusual or does not match typical inherited CAH patterns. Because these are individual reports, they cannot tell how often this happens, but they show why careful evaluation matters when pieces do not fit. [7] [8]

The fetal ovarian cyst report and the StAR deficiency series widen the range of CAH-related presentations that families might encounter in discussions with specialists. They help clarify that different genetic causes of CAH can come with different patterns of genital development and early-life complications like cholestasis in some StAR-deficiency cases. What remains uncertain is the best way to predict or prevent these less common issues, because these reports were based on small numbers. [11] [12]

The thyroid-adrenal research and the adult personality study are mainly early research about how hormones may influence the body and behavior over time. They do not show that changing thyroid levels changes CAH control, and they do not claim that personality outcomes are the same for all people with CAH. Their value is in building a clearer long-term picture of possible hormone effects that could be studied more directly in future work. [9] [10]

The education-program study suggests that short, structured training can improve DSD-related knowledge months later, which may support informed participation in care discussions for some families affected by CAH. Because there was no control group and outcomes were limited to knowledge questions, it is not clear how much it affects coping, decision-making, or health outcomes. For now, it mainly adds evidence that education can be measured and improved. [13]

The delayed-diagnosis adult CAH case underlines that missed or late recognition can have long-term physical and communication consequences, including large benign adrenal tumors and complex discussions about sex development history. This is not presented as a typical path for most people, but as an example of what can happen when CAH is not identified for decades. It also highlights that imaging interpretation and patient-centered communication can be as important as lab tests in complex situations. [14]